首页> 外文期刊>Archives of disease in childhood >P04?Barriers and facilitators to medicines adherence in children: a systematic review
【24h】

P04?Barriers and facilitators to medicines adherence in children: a systematic review

机译:P04?障碍和促进者在儿童中药物遵守:系统审查

获取原文
       

摘要

Aim Improving adherence to medicines in children with chronic conditions may lead to significant economic and health benefits. 1 To improve adherence, the multifactorial causes of poor adherence should be understood. 1 A systematic review for barriers and facilitators to medicines adherence in children was conducted seven years ago. 2 We updated this to identify barriers and facilitators to medicines adherence in children reported in the last ten years. Method A systematic literature search was performed using PubMed, EMBASE, Medline, CINAHL, IPA and Cochrane library databases covering the period November 2008 to March 2019. Inclusion criteria were original research studies identifying barriers and/or facilitators of medicines adherence in children (aged 0–18 years) and included all countries and languages. Exclusion criteria included review articles, editorials, conference papers, reports and studies in adults only. As a reliability measure, 5% of titles and abstracts were assessed independently by a second researcher. Quality assessment was performed on all included studies using the STROBE checklist for observational studies and Cochrane collaboration tools for randomised controlled studies and was checked by a second researcher. Results Of 9,360 papers identified by the search, only 172 articles met the inclusion criteria. Most studies were conducted in the US (76), with 11 in the UK, six in Canada and the remaining 79 studies in various countries. Diseases studied included: HIV/AIDS (60), asthma (25), kidney or liver diseases and transplants (18), psychiatric disorders (12), inflammatory bowel disease (10), epilepsy (9) and others (38). Various tools were used to identify barriers and facilitators to medicines adherence. These included 131 studies which used individually designed questionnaires, 32 studies used validated questionnaires and the remaining 9 studies used patients’ medical data. Forgetfulness and fear of side effects were the most common reported barriers to medicines adherence. Others reported barriers to adherence included family conflict, weak patient-provider relationships, stigma and discrimination, drug regimen complexity and lack of support from families. Factors reported to facilitate high rates of adherence included the linking of medicine taking with daily life routines, using reminders to avoid forgetfulness, a higher level of caregivers and parental education and good communication between healthcare professionals, patients and parents. Conclusion The main findings of this systematic review show that children faced many and varied barriers to medicines adherence with different diseases. Using reminders to avoid forgetfulness and good communication between healthcare professionals, patients and parents were the most common facilitators. To achieve optimal adherence, healthcare providers need to be aware of these barriers and to consider the most appropriate facilitators to encourage patients to take their medicines as prescribed.
机译:旨在改善慢性病患儿药物的粘附可能导致重大的经济和健康效益。 1为了提高遵守,应理解粘附不良的多因素原因。 1七年前举行了对儿童申请的障碍和促进者进行了系统审查。 2我们更新了这一点,以确定障碍和促进者在过去十年中报告的儿童中的药物依从性。方法使用PubMed,Embase,Medline,Cinahl,IPA和Cochrane图书馆数据库进行系统文献搜索,涵盖2008年11月至2019年3月。纳入标准是识别儿童药物依从性的障碍和/或促进者的原始研究研究(年龄0 -18岁)并包括所有国家和语言。排除标准包括仅限成人的审查文章,编辑,会议论文,报告和研究。作为可靠性措施,由第二次研究员独立评估5%的标题和摘要。通过频闪备案表来进行质量评估,用于使用频闪检查表和用于随机对照研究的Cochrane合作工具,并由第二次研究员检查。搜索结果确定了9,360篇论文,只有172篇文章达到了纳入标准。大多数研究在美国(76)中进行,英国11名,加拿大六名,剩下的各国剩余的79项研究。所研究的疾病包括:艾滋病毒/艾滋病(60),哮喘(25),肾脏或肝脏疾病和移植(18),精神病疾病(12),炎症性肠病(10),癫痫(9)和其他(38)。使用各种工具来识别药物依从性的障碍和促进者。这些包括131项使用单独设计的问卷,32项研究使用了验证问卷和剩余的9项研究患者的医疗数据。遗忘和对副作用的恐惧是药物遵守的最常见的报告障碍。其他人报告遵守的障碍包括家庭冲突,患者提供者的关系,耻辱和歧视,药物方案复杂性和家庭的支持。据报道,促进高诉讼率的因素包括将药物与日常生活惯例的联系,利用提醒来避免忘记的护理人员和父母教育,医疗保健专业人士,患者和父母之间的良好沟通。结论该系统综述的主要结果表明,儿童面临许多和不同疾病的药物依从性的障碍。使用提醒来避免健忘,医疗保健专业人员之间的良好沟通,患者和父母是最常见的促进者。为实现最佳遵守,医疗保健提供者需要了解这些障碍,并考虑最合适的促进者,以鼓励患者按规定服用药物。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号